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Abstract
In Chinese medicine, ginseng (Panax ginseng C.A. Meyer) has long been used as a general tonic or an adaptogen to
promote longevity and enhance bodily functions. It has also been claimed to be effective in combating stress, fatigue,
oxidants, cancer and diabetes mellitus. Most of the pharmacological actions of ginseng are attributed to one type of its
constituents, namely the ginsenosides. In this review, we focus on the recent advances in the study of ginsenosides on
angiogenesis which is related to many pathological conditions including tumor progression and cardiovascular
dysfunctions.         
Angiogenesis in the human body is regulated by two sets of counteracting factors, angiogenic stimulators and inhibitors.
The 'Yin and Yang' action of ginseng on angiomodulation was paralleled by the experimental data showing angiogenesis
was indeed related to the compositional ratio between ginsenosides Rg1 and Rb1. Rg1 was later found to stimulate
angiogenesis through augmenting the production of nitric oxide (NO) and vascular endothelial growth factor (VEGF).
Mechanistic studies revealed that such responses were mediated through the PI3K→Akt pathway. By means of DNA
microarray, a group of genes related to cell adhesion, migration and cytoskeleton were found to be up-regulated in
endothelial cells. These gene products may interact in a hierarchical cascade pattern to modulate cell architectural
dynamics which is concomitant to the observed phenomena in angiogenesis. By contrast, the anti-tumor and anti-
angiogenic effects of ginsenosides (e.g. Rg3 and Rh2) have been demonstrated in various models of tumor and endothelial
cells, indicating that ginsenosides with opposing activities are present in ginseng. Ginsenosides and Panax ginseng extracts
have been shown to exert protective effects on vascular dysfunctions, such as hypertension, atherosclerotic disorders
and ischemic injury. Recent work has demonstrates the target molecules of ginsenosides to be a group of nuclear steroid
hormone receptors. These lines of evidence support that the interaction between ginsenosides and various nuclear
steroid hormone receptors may explain the diverse pharmacological activities of ginseng. These findings may also lead to
development of more efficacious ginseng-derived therapeutics for angiogenesis-related diseases.       
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Panax ginseng
Background
Ginseng, Panax ginseng C.A. Meyer, a precious Chinese tra-
ditional medicinal herb, has been known clinically used
in China for thousands of years. The genus name 'Panax'
was derived from Greek. 'Pan' means 'all' and 'axos' means
'cure'. Literally 'Panax' can be translated as 'cure-all' or
panacea. The herbal root is named ginseng because it is
shaped like a man. Actually the term 'ginseng' represents
two Chinese ideograms: 'gin' (pronounced ren) refers to
'man' and 'seng' (pronounced shen) refers to 'essence' It is
believed to embody man's three mythical essences – body,
mind and spirit. Thus it is also referred to as the lord or
king of herbs [1]. Its medicinal efficacy was first docu-
mented in Shengnong Bencao Jing and it was later summa-
rized by Li Shizhen in Bencao Gangmu and Zhongyao Zhi
(Chinese Materia Medica) by People's Health Publishing
House, Beijing, published in 1596 and 1959 respectively
[1,2]. In the 18th century, the effectiveness of ginseng was
recognized in the West, and subsequently, a large number
of investigations were conducted on its botany, chemistry,
pharmacology and therapeutic applications [3-7]. Gin-
seng has been used as a general tonic or adaptogen for
promoting longevity especially in the Far East, especially
China, Korea and Japan [8]. Ginseng is now one of the
most popular herbal medicines used nutraceutically with
an annual sale of over USD 200 million.
Ginseng is a deciduous perennial plant that belongs to the
Araliaceae family. Currently, twelve species have been
identified in the genus Panax (Table 1) [9]. Among them,
Panax ginseng C. A. Meyer (Araliaceae), cultivated in
China, Korea, Japan, Russia, and the US, P. quinquefolium
L (American ginseng), grown in southern Canada and the
US and P. notoginseng, cultivated in Yunnan and Guangxi
provinces in China, represent the three most extensively
investigated species. The pharmacological and therapeutic
effects of ginseng have been demonstrated to affect the
central nervous system (CNS), cardiovascular system,
endocrine secretion, immune function, metabolism, bio-
modulating action, anti-stress, and anti-aging [5].
Recently, there have been controversies concerning the
usefulness of ginseng in cancer therapy. Most studies
claimed that the pharmacological effects of ginseng are
attributed to its bioactive constituents such as ginseno-
sides, saponins, phytosterols, peptides, polysaccharides,
fatty acids, polyacetylenes, vitamins and minerals [10]. In
this review, we focus on the recent advances in the studies
of ginsenosides on the modulation of angiogenesis (i.e.
formation of blood vessels) which is a common denomi-
nator of many diseases, such as tumor and cardiovascular
disorders (e.g. atherosclerosis).
Ginsenosides of ginseng
The most prominent constituent of ginseng is a saponin
glycoside known as ginsenosides (Rx) (Figure 1). Recent
research indicates that most of the pharmacological effects
of ginseng are attributed to ginsenosides [11]. In general,
the contents of ginsenosides vary widely ranging from 2 to
20% depending on the species, age and part of ginseng,
and even vary with the preservation or extraction method
[11-13]. More than 30 ginsenosides have been isolated,
and characterized from various Panax species [14,15]. In
terms of their chemical structural characteristics, ginseno-
sides can be classified into three major categories, namely
protopanaxadiols (PPD) (e.g. Rb1, Rb2, Rc, Rd, Rg3, Rh2),
protopanaxatriols (PPT) (e.g. Re, Rf, Rg1, Rg2, Rh1) and
the oleanolic acid derivatives. Ginsenosides have a ster-
oid-like skeleton consisting of four trans-rings, with mod-
ifications from each other depending the type (e.g.
glucose, maltose and fructose), number of sugar moieties
and the sites of attachment of the hydroxyl group (e.g. C-
3, C-6, or C-20) (Figure 1). Ginsenosides are amphipathic
in nature. The hydroxyl (-OH) group of ginsenosides
allows both interactions between the polar head of the
membrane phospholipids and the β-OH group of choles-
terol, while the hydrophobic steroid backbone can inter-
act with the hydrophobic side chains of fatty acids and
cholesterol. Indeed, these physiochemical interactions are
greatly determined by the numbers and sites of polar
hydroxyl groups on each ginsenoside. Moreover, ginseno-
sides have been shown to interact with numerous mem-
brane proteins such as ion channels, transporters and
receptors, which leads to a broad range of physiological
activities [16].
Angiogenesis
The term 'angiogenesis', first used by Hertig in 1935, refers
to the formation of new blood vessels in the placenta [17].
Angiogenesis is a complex multi-step process which com-
prises activation, chemotactic invasion and migration,
morphological alteration, proliferation, and capillary
tube formation of endothelial cells (ECs) from pre-exist-
ing blood vessels (Figure 2). In this process, ECs have
been shown to express all the information necessary to
construct a vascular network. Under normal physiological
conditions, most vasculature is quiescent, with only
0.01% of the ECs undergoing active cell division; thus
angiogenesis is a relatively rare event that specifically
occurs for a short and defined time period [18,19]. In
addition, it is also tightly controlled by a relative balance
of two groups of counteracting factors, namely angiogenic
stimulators and inhibitors [20] (Figure 3).
Sprouting and intussuceptive (non-sprouting) modes of 
angiogenesis
Sprouting angiogenesis consists of several consecutive
steps with extensive interactions between soluble factors,Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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extracellular matrix (ECM) and cells. As shown in Figure
2, during the early stage of angiogenesis, angiogenic fac-
tors such as vascular endothelial growth factor (VEGF)
and fibroblast growth factor (FGF) emanate from condi-
tioned cells (e.g. stromal cells, endothelial cells, blood) or
surrounding tissues (e.g. ECM) to stimulate ECs [19].
These activated ECs secrete various types of enzymes
including matrix metalloproteinases (MMPs), plasmino-
gen activators (PA), gelatinase, collagenases and uroki-
nases which bring about the degradation of basement
membrane and ECM surrounding the parental blood ves-
sels. Subsequently, the ECs migrate towards the ang-
iogenic factors with the help of surface adhesion
molecules or integrin receptors such as intercellular adhe-
sion molecule-1 (ICAM-1), vascular cell adhesion mole-
cule-1 (VCAM-1) and integrins αvβ3 [21,22]. Upon the
induction of various angiogenic factors, ECs proliferate
and align in a bipolar mode to form capillary sprouts.
Finally, these ECs form a lumen and a capillary loop
through which the blood can flow.
Intussusceptive microvascular growth, a novel mecha-
nism of blood vessel formation and remodeling, occurs
by internal division of the pre-existing capillary plexus
without sprouting. It is initiated by protrusion of oppos-
ing capillary walls into the lumen where a contact is cre-
ated between the ECs. Then the endothelial bilayer is
perforated and numerous transcapillary tissue pillars with
an interstitial core are formed. An extensive vascular tree
is formed from the subsequent intussusceptive pillar for-
mation and pillar fusions [23-25].
Molecular regulation of angiogenesis
Among the angiogenic regulators, VEGF and nitric oxide
(NO) are the critical angiogenic stimulators. We have
demonstrated that they are closely related to ginsenoside-
mediated angiomodulation. Both VEGF and NO play a
critical role in the regulation of physiological angiogen-
esis including embryogenesis, reproduction and wound
healing. They have also been implicated in pathological
angiogenesis associated with tumors or many cardiovas-
Table 1: Species of Ginseng belonging to the genus Panax.
Scientific name Common name (English 
name)
Geographical distribution
Panax ginseng C.A. Meyer Asian ginseng
Orient Ginseng
Chinese Ginseng
Korean Ginseng
Red Ginseng
White Ginseng
Tartary Ginseng
Tartary Root
Kirin Ginseng
Korea
Japan
China
Russia
Germany
Panax japonicus C.A. Meyer Japanese Ginseng
ChiKu
East, Middle-south, South and South Yunnan
Japan
Panax bipinnatifidus Seem Feather-leaf bamboo ginseng
Feather-leaved bamboo ginseng
Hubei, China
Nepal
Eastern Himalayas
Panax notoginseng (Burkill) F.H. Chen Sanchi Ginseng
Tienchi Ginseng
Sanchu Ginseng
Notoginseng
San-qi ginseng
Tien-qi ginseng
Yunnan ginseng
Yunnan, Guangxi
Guangdong, China
Panax omeiensis J. Wen Omei ginseng Sichuan, China
Nepal
Eastern Himalayas
Panax pseudoginseng Wallich Himalayan Ginseng South Tibet
Nepal
Eastern Himalayas
Panax quinquefolius L. American Ginseng
Occidental Ginseng
Canadian Ginseng
Northeast, North, East China
Southern Canada
America (from Maine to Minnesota, south to Florida and west to 
Oklahoma)
Panax stipuleanatus H.T. Tsai and K.M. Feng Pingpien ginseng
Baisanqi
Tusangi
Yesangi
Zhujie qi
Southern Yunnan, China
Panax trifolius L. Dwarf ginseng
Groundnut
Ohio
Pennsylvania
Nova Scotia to Wisconsin and further south
Panax wangianus S.C. Sun Narrow-leaved pseudoginseng Sichuan, China
Panax vietnamensis Ha et Grushv. Bamboo ginseng
Vietnamese Ginseng
Panax zingiberensis C.Y. Wu and K.M. Feng Ginger ginseng
Ginger-like Pseudo-ginseng
Yunnan, China
[References: 5, 8, 9, MULTILINGUAL MULTISCRIPT PLANT NAME DATABASE-http://www.plantnames.unimelb.edu.au/Sorting/Panax.html#bipinnatifidus and Ginseng: A 
Concise Handbook. Edited by James A, Duke. Reference Publications, Inc. 1989. Michigan, USA]Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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The chemical structure of ginsenosides [6] Figure 1
The chemical structure of ginsenosides [6]. glc = glucosyl (C6H11O6
-); rha = rhamnosyl (C6H11O5
-); ara = arabinosyl 
(C5H9O5
-); p = pyran; f = furan.
Ginsenoside R1 R 2 R 3
Protopanaxatriol
Rg1 H -O-glc glc 
Rg2 H -O-glc(2-1)rha H 
Re  H -O-glc(2-1)rha glc 
Rf  H -O-glc(2-1)glc H 
Rh1 H -O-glc H 
F1  H -OH  glc
    
Protopanaxadiol
Rb1 glc(2-1)glc H  glc(6-1)glc
Rb2 glc(2-1)glc H  glc(6-1)ara(p) 
Rg3 glc(2-1)glc H  H 
Rh2 glc  H H 
Rc  glc(2-1)glc  H  glc(6-1)ara(f) 
Rd  glc(2-1)glc  H  glc 
Ra  glc(2-1)glc  H  glc(6-1)glc 
F2  glc  H glc
Compound Y  H  H  glc(6-1)ara(p)
Compound K  H  H  glc 
Compound O  glc  H  glc(6-1)ara(p)
Compound Mc  glc  H  glc(6-1)ara(f) Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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The process of angiogenesis Figure 2
The process of angiogenesis. A) Sprouting angiogenesis: formation of blood vessels is a multi-step process, which includes 
(i) reception of angiogenic signals (yellow spot) from the surrounding by endothelial cells (EC); (ii) retraction of pericytes from 
the abluminal surface of capillary and secretion of protease from activated endothelial cells (aEC) and proteolytic degradation 
of extracellular membrane (green dash-line); (iii) chemotactic migration of EC under the induction of angiogenic stimulators; 
(iv) proliferation of EC and formation of lumen/canalisation by fusion of formed vessels with formation of tight junctions; (v) 
recruitment of pericytes and deposition of new basement membrane and initiation of blood flow. B) Non-sprouting angiogen-
esis – intussusceptive microvascular growth: it is initiated by (i) protrusion of opposing capillary walls towards the lumen; (ii) 
perforation of the EC bilayer and formation of many transcapillaries with interstitial core (red arrow); (iii) formation of the vas-
cular tree from intussusceptive pillar formation and pillar fusion and elongation of capillaries (green arrows).
(A) 
(B)Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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cular disorders (such as atherosclerosis or ischemic
injury). VEGF, which belongs to the VEGF family, is
expressed in different tissues including the brain, liver,
spleen and many cell types [26]. In vitro, VEGF not only
acts as a survival factor and mitogen for ECs, but also
induces the expression of many angiogenesis-related fac-
tors, including ICAM-1, VCAM-1, uPA, PAI-1, uPAR and
MMPs. All these gene products are related to the increase
of ECM degradation, migration and tube formation of
ECs, whereas their effects on intussusception remain to be
investigated [27-30]. The critical roles played by VEGF in
embryonic vasculogenesis and angiogenesis have been
demonstrated [31,32]. Inactivation of a single VEGF allele
in mice resulted in embryonic lethality between days 11
and 12. The growth of VEGF+/- embryos was retarded and
there were many developmental anomalies.
Endothelium-derived NO has been implicated in mediat-
ing a multiplicity of processes involved in angiogenesis. In
fact, there are many angiogenic factors, such as VEGF,
transforming growth factor β (TGF-β) and fibroblast
growth factor (FGF), which can up-regulate the expression
of endothelial NO synthase (eNOS), thereby inducing the
release of NO [33-36]. VEGF- or bFGF-activated human
umbilical vein endothelial cells (HUVEC) have been
found to secrete NO on Matrigel substratum and subse-
The balance hypothesis of the 'angiogenic switch' Figure 3
The balance hypothesis of the 'angiogenic switch'. Angiogenesis is tightly controlled by the balance of two sets of coun-
teracting factors – angiogenic activators and inhibitors. The stability of 'angiogenic switch' determines the time of initiation of 
the subsequent angiogenic process. When there are more angiogenic stimulators than angiogenic inhibitors, as in the case of 
solid tumors, normal wound healing or female endometrial repair, the 'angiogenic switch' will be turned on and angiogenesis 
will proceed. Furthermore, during the process, each step is strictly mediated by the balance of different types of angiogenic 
stimulators or inhibitors. In some pathological cases, the 'angiogenic switch' remains in the 'ON' mode which leads to 'non-
stop' formation of new blood vessels and ultimately many physiological disorders and diseases.Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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quently form a tube-like structure, whereas such tube for-
mating action is abolished by eNOS antagonist, Nω-nitro-
L-arginine methylester (L-NAME) [37-39]. On the one
hand, NO increases EC proliferation by acting as a sur-
vival factor and enhances migration by augmenting the
expression of αvβ3 and matrix-ECs interaction through the
up-regulation of uPA [40-44]. Moreover, its vasodilating
activity is the most prominent effect shown in the modu-
lation of cardiovascular physiology [45]. On the other
hand, disruption of the eNOS pathway can result in an
impairment of normal angiogenesis, enhancement of
tumor pathogenesis, and cardiovascular disorders [46-
49].
VEGF and NO are working closely with each other in the
modulation of angiogenesis, whereas NO is both an
upstream and a downstream mediator or an effector of
VEGF-dependent angiogenesis. Upon binding to its recep-
tors, VEGF initiates complicated signaling cascades result-
ing in NO production and subsequent activation of ECs
and smooth muscle cells in vessels, keratinocytes and
macrophages in wounds, and tumor cells. Furthermore,
through the activation of the PI3K/Akt pathway, NO can
increase VEGF synthesis in a positive feedback manner
[46,50-54].
Angiogenesis in health and diseases
Normal physiology
In health, angiogenesis is under stringent control by an
'angiogenic switch' (Figure 3), and rarely occurs in adults
except for embryogenesis, placentation, endometrial
repair and wound healing [20,55]. In the latter case, for-
mation of neovessels is necessary to sustain newly formed
granulation tissues, in such a way that the ECs divide with
a turnover rate of about 5 days, giving rise to a new micro-
vascular network. During the menstrual cycle, however,
angiogenesis occurs in corpora lutea and endometrium
with rapid growth and regression [56-59]. Thus angiogen-
esis is normally in the quiescent state but is capable of
both rapid activation and shutting down.
Pathophysiology
Excessive angiogenesis has been defined as a prominent
pathological feature of many diseases such as tumor,
rheumatoid arthritis, atherosclerosis, psoriasis and dia-
betic retinopathy [60-63] (Table 2). During the early stage
of tumorigenesis, tumors are usually not angiogenic (Fig-
ure 4). Since oxygen can only diffuse to around 150–200
microns from capillaries, solid tumors can only grow to
1–2 mm3 autonomously at which stage they may exist for
months or years without neovascularization (i.e. avascu-
lar phase). However, once tumor cells switch to the ang-
iogenic phenotype (i.e. vascular phase), an extensive
vascular network is constructed through sprouting or non-
sprouting angiogenic mechanisms. The large amounts of
angiogenic factors, mainly VEGF secreted by tumor cells
or activated ECs, form a positive feedback on angiogen-
esis, leading to tumor growth and subsequent metastasis.
[64,65]. A similar case has also been found in atheroscle-
rosis, in which excessive angiogenesis enhances plaque
growth in such a way to sustain perfusion, increase leuko-
cyte exchange, deposition of proatherogenic plasma mol-
ecules and finally promote intraplague hemorrhage [66].
An insufficient amount of angiogenic stimulators and/or
an excess of angiogenic inhibitors can tip the balance
resulting in inadequate or limited angiogenesis. Inade-
quate angiogenesis can also cause serious pathological
outcomes such as stroke, Alzheimer disease, chronic
wound, ulceration, ischemic coronary artery, critical limb
ischemia, hypertension and hair loss [62,63]. In diseases
such as ischemic coronary artery or limb ischemia, the
functional blood flow is partially lost in certain organs or
limbs. Poor blood circulation greatly prolongs the recov-
ery period or even results in morbidity or death. A similar
phenomenon has been found in the aberrant wound
repair in diabetic and gastric ulcer [67,68].
Angiotherapy: angiogenesis as a therapeutic 
target
Since the discovery in the early 1970s that tumor progres-
sion is angiogenesis-dependent, the concept of 'angiother-
apy' has been hypothesized as a therapeutic strategy [69].
Ideally, this strategy could be used in the case of insuffi-
cient angiogenesis (e.g. heart ischemia) through the stim-
ulation of neovessel formation by introducing angiogenic
stimulators. An over-burst of uncontrolled angiogenesis
(e.g. tumors) could be treated using angiogenic inhibitors
to shut down the formation of neovessels [70-72] (Table
2). After thirty years, this idea became a reality when the
first-generation anti-angiogenic drugs called Avastin (bev-
acizumab) and Macugen (pegaptanib sodium) were
approved by the Food and Drug Administration in the US
in 2004 and 2005 respectively for clinical application in
cancer patients [73].
In fact, a large number of anti-angiogenic agents (e.g. tha-
lidomide, TNP-470, endostatin, and angiostatin) are
being tested or undergoing preclinical or clinical trials
either alone or in combination with conventional thera-
pies [74-76]. Most of these drugs target the ECs rather
than tumor cells, thereby affecting different stages of ang-
iogenesis. Therefore, they are less likely to cause bone
marrow suppression, gastrointestinal symptoms or hair
loss than conventional tumor therapies.
Pharmacological actions of ginsenosides
Anti-tumor effects of ginsenosides
In Asia, ginseng has been used as a medicinal herb for a
long time to treat various ailments such as malignant dis-Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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eases. Experimental studies from the past two decades
have shown that both the anti-tumor activities and thera-
peutic effects of ginseng are mainly attributed to ginseno-
sides which induce cell death and inhibit metastasis.
Induction of cell death
Several patterns of eukaryotic cell death, namely apopto-
sis, autophagy, paraptosis, mitotic catastrophe and necro-
sis, have been recognized [77-79]. The process of cell
death can be either caspase-dependent or caspase-inde-
pendent. It is also known that mitochondria play an
important role in the initiation of apoptosis. Different
ginsenosides induce apoptosis through various signaling
cascades. Rh2 and compound K (the metabolites of Rb1)
have been shown to induce apoptosis in prostate cancer
cells, ovarian cancer cells, neuroblastoma cells and A549
lung adenocarcinoma cells by activating caspase-3 and -8
[80-83]. Kim et al. further demonstrated that such apop-
totic activation can be Bcl-2, Bcl-xL or Bax independent
[84-87]. In human neuroblastoma (SK-N-BE) and rat gli-
oma models, Rh2-induced apoptotic cell death has been
implicated via protein kinase C (PKC) and reactive oxy-
gen-dependent mechanisms [88-90]. The apoptotsis –
inducing activities of other ginsenosides such as Rb2, Rc,
Rg3, RS4  and IH901 (20-O-(beta-D-glucopyranosyl)-
20(S)-protopanaxadiol, an intestinal bacterial metabolite
of ginseng formed from Rb1, Rb2 and Rc, have also been
observed in different human tumor cell lines [87-89].
These findings suggest that induction of tumor cell apop-
tosis by ginsenosides may be one of the mechanisms in
the elimination of tumor cells.
Anti-proliferation
Inhibition of cell cycle progression has also been impli-
cated as a chemopreventive mechanism of ginsenosides.
Rh2, Rg3, IH901 and PD have been shown to arrest the
growth of human tumor cell lines such as A549 lung
tumor cells, LNCaP and PC3 prostate carcinoma cells,
U937 leukemia cells, SK-HEP-1 hepatoma cells and HeLa
cells [80-83,91]. Mechanistically, Rh2 has been shown to
arrest the cell cycle at the G1/G0 phase, and to prolong the
S-phase in intestinal (Int-407 and Caco-2) cells and SK-
HEP-1 hepatoma cells [92-94]. It also induces cell arrest
by down-regulation of cyclin/Cdk complex kinase activ-
ity, inhibition of E2F release in MCF-7 breast carcinoma
cells, or by modulation of three modules of MAP kinases
in prostate carcinoma cells [81,95].
Active growth of tumor cells can also be attenuated by
induction of terminal differentiation and this approach
has been developed as one of the strategies in cancer treat-
ment [96]. Previously, Zeng and Tu showed that Rh2-
treated hepatocarcinoma (SMMC-7721) cells exhibited
the morphological characteristics of mature cells. Results
showed that Rh2 can reduce telomerase activity which
affects transcriptional activity in cells and facilitates both
cell differentiation and cell arrest [97,98]. Moreover, Rh2-
induced cell differentiation has also been found in B16
melanoma cells and F9 teratocarcinoma cells [99,100].
Table 2: Angiogenic diseases
Diseases/disorders Organ/organ system
Atherosclerosis
hypertension
Vascular dementia
Haemangioma
Haemangioendothelioma
Ischemic heart, limb
Cardiovascular system
Diabetic retinopathy
Ischemic retinopathy
Neovascular glaucoma
Cancer
Ocular
Warts
Kaposi's sarcoma
Neoplasms
Psoriasis
Ulcer
Skin
Dysfunctional uterine bleeding
Endometriosis
Neoplasms
Placental insufficiency
Cancer
Reproductive system
Rheumatoid arthritis Bones, joints
Ulcer
Cancer
Crohn's disease
Digestive systemChinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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After Rh2 treatment, B16 cells resembled epithelioid cells
morphologically and the cells were arrested at the G1
phase. In vitro induction of differentiation of F9 cells was
shown to involve the glucocorticoid receptor (GR). In the
presence of a glucocorticoid antagonist (RU486), Rh1- or
Rh2-treated F9 cells did not differentiate into endoderm-
like cells. These hypotheses were further corroborated in
the gel mobility shift assay, in which the glucocorticoid
responsive element (GRE) was specifically detected,
mainly in the nuclear extract of ginsenoside-treated F9
cells. Concomitantly the results were also recorded in the
luciferase-reported gene assay.
Anti-invasion and metastasis
Cancer metastasis is a complex process involving angio-
genesis and cell-cell interactions. Enzymes such as matrix
A fundamental step in tumorigenesis – angiogenesis Figure 4
A fundamental step in tumorigenesis – angiogenesis. Angiogenesis is a critical step in the pathogenesis of solid tumors. 
Tumors remain in a dormant state (avascular phase) for a long time (up to several years), in which tumors keep their size 
within 1 – 2 mm3. When tumor progression starts, tumor cells secrete a large amount of angiogenic factors, mainly VEGF, to 
the surrounding tissues and blood capillaries. Once tumor angiogenesis is initiated, tumors enter a 'vascular phase' and become 
more aggressive. These newly formed blood vessels provide tumor cells with oxygen and nutrients for them to grow and for 
the initiation of metastasis.Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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metalloproteinases are known to play an important role
in tumor invasion, metastasis as well as initiation of ang-
iogenesis. Fujimoto et al. recently demonstrated that the
invasiveness of the endometrial cancer cell lines HHUA
and HEC-1-A was inhibited by treating the cells with gin-
senoside Rb2 [101]. The inhibitory effect is due to suppres-
sion of MMP-2 expression. The association between
down-regulation of MMP expression and reduction of
invasiveness was also demonstrated in a highly metastatic
HT1080 human fibroblast cell line. Purified ginseng com-
ponents, PD and PT, down-regulated the expression of
MMP-9 in HT1080 cells [102]. By contrast, the expression
of MMP-2 was not affected by PD and PT. Whether the
observed differential inhibition of MMP-2 and MMP-9
expression in these two groups of cells is cell type- or gin-
senoside-dependent remains to be elucidated.
In addition, the anti-invasive effects of Rb2, 20(S)- and
20(R)-Rg3 have been further demonstrated by Shinkai et
al. [103] and Mochizuki et al. [104]. Rg3 was found to sig-
nificantly inhibit in vitro invasion of rat ascites hepatoma
cells (MM1), B16FE7 melanoma cells, human lung carci-
noma (OC10) and pancreatic adenocarcinoma (PSN-1)
cells. Intravenous (10 μg/mouse) or oral (100–1000 μg/
animal) administration of both Rg3 and Rb1 inhibited
lung metastasis of B16-BL6 melanoma and colon 26-
M3.1 carcinoma in mice [103-105]. Furthermore, Rg3
greatly reduced the volume or weight of tumors in
xenotransplanted (e.g. Lewis lung carcinoma, human
breast infiltrating duct carcinoma, human gastric tumor
and B16-BL6 melanoma) or chemical-induced (e.g. hepa-
tocellular carcinoma) tumor models [106-109].
Effects of ginsenosides on multi-drug resistance
The development of multi-drug resistance (MDR) is a
major problem in cancer chemotherapy. Agents that can
enhance the accumulation of chemotherapeutic drugs in
tumor cells by targeting the MDR proteins is a novel
approach to overcome this problem [110-112]. In an
acute myelogenous leukemia cell model, PPT ginseno-
sides were found to exert a chemosensitizing effect on P-
glycoprotein (Pgp)-mediated MDR leukemia cells by
increasing intracellular accumulation of daunorubicin
and doxorubicin [113]. The effect on the reversal of drug
resistance was due to competitive binding of ginsenosides
such as Rg3 with Pgp, thereby blocking drug efflux [114].
In other MDR leukemia cells such as daunomycin or vin-
blastine-resistant leukemia cell models, various ginseno-
sides including 20(S)-PPT, Rh2 and compound K were
found to greatly enhance the cytotoxicity of anti-cancer
drugs in a range of 2- to 46-fold through the blockage of
drug efflux [115]. Moreover, other ginsenosides including
Rc and Rd reduced the efflux pump activity in lymphoma
cells [116]. Recently, we also demonstrated that ginseno-
sides could exert the chemosensitizing effect through
direct interaction with breast cancer resistance protein
(BCRP), but not Pgp in MCF-7 cells. Among the tested
ginsenosides, Rh2, PPD and PPT have been found to
increase the cytotoxicity of mitoxantrone (MX), a potent
anti-tumor drug, to human breast carcinoma MCF/MX
cells which overexpress BCRP. The potency order of ginse-
nosides to inhibit BCRP is PPD > Rh2 > PPT. Neither Rg1
nor Rh1 was observed to inhibit BCRP or Pgp, whereas Rg3
was shown to be mild inhibitors. Previously, the C-6 sub-
stitution was hypothesized to confer anti-tumor activity.
These findings suggest that the C-6 substitution is also
important to the BCRP-inhibitory activity of ginsenosides.
In addition, the two glucose substitutions at C-3 position
such as Rg3 nearly abrogate its effect to inhibit BCRP. Our
findings indicated that the inhibition of MX efflux as
mediated by BCRP and the enhanced uptake of MX is cor-
related to the attachment of the hydroxyl group and sugar
substitution at different positions of the steroidal skeleton
of ginsenosides [117].
A new class of anti-tumor drugs: ginsenosides Rg3 and Rh2
Both Rg3 and its metabolite form Rh2 have emerged in
Mainland China and Taiwan as anti-cancer drugs in the
form of capsules (e.g. 'Rg3 Shenyi Jiaonang' and 'GOOD
LIFE ginsenoside Rh2 capsule'). Rg3 Shenyi Jiaonang sup-
presses tumor angiogenesis and prevents adhesion, inva-
sion and metastasis of tumor cells [118]. Rh2  as an
adjuvant agent was also tested in the nude mouse model
with human ovarian cancer cells transplanted. In the pres-
ence of Rh2, cisplatin could significantly inhibit tumor
growth in vivo and prolong survival time. Neither Rh2 nor
cisplatin alone could inhibit tumor growth [119]. It was
shown that chemotherapy supplemented with Rh2 is 60%
more effective than chemotherapy alone. It could also
mitigate the adverse effects of hair loss, anemia, nausea,
vomit and poor appetite following chemotherapy or radi-
otherapy [120].
Both Rg3 and Rh2 are extracted from red ginseng which is
processed by steaming and drying. During the process, the
malonyl group at the C-6 is released and the glycosyl moi-
ety at C-20 is partially detached to generate Rh1, Rh2 and
Rg3 through deglycosylation similar to the deglycosylated
product, compound K generated from the metabolic
transformation of ginsenoside Rb1 by intestinal bacteria
[121,122]. However, whether all of the ginsenosides gen-
erated by such post-treatment of white ginseng have sim-
ilar anti-tumor effects are still not known.
Anti-angiogenic effects of ginsenosides
Various ginsenosides including Rg3, Rb2 and compound K
demonstrated anti-angiogenic activity in different tumor
models. Among them, Rg3 is the most extensively investi-
gated. It exerts an anti-angiogenic action in different ani-
mal models when administered alone or in combinationChinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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with other conventional chemicals. In those animal mod-
els which have been orthotopically implanted with differ-
ent tumor cells such as human breast infiltrating duct
carcinoma, ovarian carcinoma SKOV3 cells, B16-BL6
melanoma cells and colon 26-M3.1 carcinoma, Rg3 or Rb2
was found to inhibit angiogenesis in vivo. A significant
reduction of intra-tumoral microvessel density (MVD),
VEGF mRNA and VEGF protein levels in tumor tissues and
sera of the tumor-bearing animals was observed [104-
106,122]. Similar results were also reported when Rg3 was
used in combination with a low dose of cyclophospha-
mide in bearing mice Lewis lung carcinoma [109]. These
data indicate that one of the mechanisms of anti-meta-
static effect of ginsenosides is probably related to suppres-
sion of tumor-induced angiogenesis [104].
In a recent study, we demonstrated that 20(R)-Rg3 (1–103
nM) was able to inhibit HUVEC proliferation, VEGF-
induced chemoinvasion and tubulogenesis in vitro in a
dose-dependent manner. In a Matrigel plug assay, 20(R)-
Rg3 (600 nM) was able to reduce the hemoglobin content
by 5-fold when compared with the positive control con-
taining bFGF and heparin. The extent of microvascular
sprouting was inhibited dose-dependently by 20(R)-Rg3
in the ex vivo organtypic cultures of rat aortic ring frag-
ments (Figure 5). Basement membrane degrading
enzymes, especially MMP-2 and -9, are secreted by acti-
vated ECs (or even tumor cells) throughout the ang-
iogenic process. They have been demonstrated to play a
critical role in cell invasion and migration, as well as ang-
iogenesis. Our data further demonstrate that the anti-ang-
iogenic effect of 20(R)-Rg3  was probably related to
reduction of expression and activities of MMP-2 and -9
[124]. By using DNA microarray, 20(R)-Rg3 was found to
inhibit the protein expression of angiogenic factors via
several target genes (e.g. VEGF, bFGF and MMP-2) in both
human lung adenocarcinoma cell line A549 and
HUVEC304 cells [123]. Current research findings, indicat-
ing that some PD type ginsenosides (e.g. Rg3 and Rb2)
exhibit potent anti-tumor and anti-angiogenic activities in
vitro and in vivo, have far-reaching implications for future
development of ginsenosides as an anti-tumor medicine.
Angiogenic effects of ginsenosides
In contrast to the anti-angiogenic effects of ginsenosides
such as Rb1 and Rg3, another group of ginsenosides, rep-
resented by the panaxatriols Rg1 and Re, have been found
to be angiogenic. Rg1  increased HUVEC proliferation,
migration and tube formation in a dose-dependent man-
ner [125-128]. We further demonstrated its angiogenic
effects using the in vivo Matrigel plug and ex vivo aortic ring
sprouting models (Figure 5). Histological evaluation of
the Matrigel implants indicated that functional neovessels
were formed as induced by Rg1. The in vivo data collected
seven days after the implantation of genipin-fixed porous
acellular bovine pericardium (same as extracellular matri-
ces), which was dip-coated with Re or Rg1, indicate that
the density of neovessels and tissue hemoglobin content
inside the matrices were significantly increased by both
ginsenosides. Furthermore, vascularized neo-connective
tissue fibrils were found to fill the pores in the matrices
loaded with Re [125]. Similar angiogenic activities were
also observed in the above assays when Rg1 was used
[126]. Interestingly, ginsenoside-induced angiogenesis
was found to be comparable to or even better than bFGF-
induced angiogenesis in vivo. These data suggest that both
ginsenosides are very potent angiogenic agents and may
potentially be useful in therapeutic angiogenesis in tissue-
engineering strategies
Ginseng contains two groups of ginsenosides with activity
in the modulation of angiogenesis. These observed coun-
teracting effects can be interpreted by the Yin/Yang theory
in traditional Chinese medicine (TCM). In fact, we have,
in our previous publications, demonstrated strong scien-
tific evidence supporting the ancient Yin/Yang theory
[129]. Administration of Rg1 or Rb1 alone was shown to
exert counteracting effects in angiogenesis. Rg1 alone pro-
moted functional neovascularization in the polymer scaf-
fold in Matrigel implant model and the chemoinvasion of
HUVEC. By contract, Rb1  exerted inhibition in both.
Moreover, we found that ginseng extract reconstituted
with a defined ratio of Rg1 and Rb1 could alter the ang-
iogenic outcome. In an in vivo scaffold implant neovascu-
larization model, administration of an extract with a
higher concentration of Rg1  than Rb1  (Rg1:Rb1  = 5:2)
resulted in the induction of significant angiogenesis in the
implant compared with control implants. In contrast,
overabundance of Rb1  (Rg1:Rb1  = 2:5) inhibited Rg1-
induced neovascularization [130]. These counteracting
actions manifested the logic of Yin/Yang theory of TCM,
which advocates that everything has opposing Yin and
Yang aspects, and these aspects are reciprocally regulated
and inhibited by each other in such a way that a continu-
ous state of dynamic balance is maintained. The contents
of ginsenosides in P. ginseng, P. quinquefolius and P. noto-
ginseng were then measured by an HPLC method. The data
show that P. ginseng has a higher ratio of Rg1 to Rb1 (0.51
– 2.08), while P. quinquefolius has a lower ratio (0.07 –
1.4) [131,132]. These findings are also consistent with the
TCM's attributes of 'hot' (i.e. stimulating) properties of P.
ginseng and 'cool' (i.e. calming) properties of P. quinquefo-
lius.
Functional genomics approach on the mechanistic study of 
ginsenoside
Functional genomics refers to the functions and interac-
tions of genes towards a holistic view of the biological sys-
tem in terms of gene expression and proteins. It focuses
on the dynamics of gene transcription, translation andChinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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protein-protein interactions, instead of the static views of
genomic information (e.g. gene sequences). It can be
achieved by means of transcriptomics (differential expres-
sion of genes), proteomics (the study of total protein com-
plement of a genome), phosphoproteomics and
metabolomics studies (the study of the entire metabolic
content of a cell or an organism). In general, the func-
tional genomics approach is accompanied by high-
throughput technology platforms such as the DNA micro-
array (i.e. DNA chip) technology and two-dimensional gel
electrophoresis (2-DE) coupled with mass spectrometry
for characterization of the abundant gene and protein
products. The chip-based microarray allows a quantitative
parallel assessment of gene expression and facilitates the
study of complicated drug actions at the molecular level.
This rapid increase in functional genomic-based drug
studies enables an early and more accurate prediction and
diagnosis of disease and disease progression. Understand-
ing of the individual responses to drugs will have implica-
Angiogenesis assays Figure 5
Angiogenesis assays. Angiogenesis is a multi-step process, Different types of in vitro, in vivo or ex vivo bioassays have been 
designed to mimic the various steps of angiogenesis. (A) In vivo Matrigel Plug assay: liquid form Matrigel (500 μl) containing 
growth factor (e.g. bFGF) and/or ginsenoside is injected into the abdominal region of C57/BL mice subcutaneously. The 
Matrigel will solidify at 37°C and form a solid 'plug'. After 5 days of incubation, the mice are sacrificed and in vivo angiogenesis 
including endothelial cell invasion, migration and formation of neovessels can be examined [124]. (B) Ex vivo rat aortic ring 
sprouting assay: rat aortic fragments one millimeter in length are embedded in Matrigel and cultured in the presence of growth 
factors (e.g. endothelial cell growth supplements – ECGS) and/or ginsenosides. The extent of endothelial sprouting from the 
aortic fragment can clearly indicate the angiogenic properties of ginsenosides [124]. (C) In vivo sponge implantation assay: a 
sterile polyether polyurethane sponge (170 mm3) containing ginsenosides is inserted into the abdominal region of Balb/c mice. 
After incubation for 15 days, the animals are euthanized and neovascularization is examined as indicated by the growth of ves-
sels in the granuloma tissue [129]. (D) In vitro tube formation assay: endothelial cells are seeded on the Matrigel and subse-
quently incubated in medium containing growth factors (e.g. VEGF) and/or ginsenosides. Endothelial cells will rearrange and 
alight into a tubular structure. Angiogenic properties of ginsenosides can be reflected from the number of tubes, branching 
points or tube area.Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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tions for their use and development by the
pharmaceutical industry.
This approach was applied in the mechanistic study of
ginsenoside Rg1 on HUVEC [127,133]. Our microarray
data indicated that ginsenoside Rg1 could up-regulate a set
of genes related to cell adhesion, migration and cytoskel-
eton such as RhoA, RhoB, IQ-motif-containing GTPase-
activating protein 1 (IQGAP1), calmodulin (CALM2),
Vav2 and laminin-α4 (LAMA4) in HUVEC. These proteins
interact with one another in a hierarchical cascade pattern
in modulating cell architectural dynamics. As we observed
in the tube formation assay, HUVEC undergo rapid migra-
tion and morphological differentiation to form tubular
structures by involving a dynamic assembly and disassem-
bly of cytoskeletons. RhoA and RhoB, which belong to
Rho family GTPases, have been found to regulate cell-cell
adhesion and hence the motility through interfering with
membrane ruffling, stress fiber formation and E-cadherin-
mediated cell-cell adhesions [134-142]. The activities of
GTPases are regulated by means of a molecular switch;
cycling of the GDP-bound form (inactive state) and GTP-
bound form (active state). As demonstrated by Bustelo et
al., such transformation can be activated by guanine
nucleotide exchange factors (Rho-GEFs) [143,144]. Vav2,
one of Rho-GEFs, can increase the exchange of bound-
GDP for a GTP molecule and translocate the Rho GTPases
to the plasma membrane for interaction with its Rho
effectors such as IQGAP1 [145]. Moreover, Vav2 can also
affect cadherin-mediated cell-cell adhesion by binding
with p120 catenin leading to formation of lamellipodia
and membrane ruffling [146-148]. IQGAP1 acts as a neg-
ative regulator in E-cadherin-mediated cell-cell adhesion
by interacting directly with β-catenin and the cytoplasmic
domain of cadherin [149,150]. Over-expression of
IQGAP1 is believed to compete with α-catenin for the
same binding site on β-catenin and displace α-catenin
from the β-catenin-α-catenin complex which disrupts the
association of the complex with F-actin. Such cytome-
chanical modifications can subsequently cause the reduc-
tion of E-cadherin-mediated cell-cell adhesion that
accounts for the changes in cell morphology and migra-
tion [151]. Moreover, laminins, which are the trimeric
basement membrane glycoproteins, have been found to
participate in the formation and differentiation of tubular
structures of HUVEC in vitro and to provide a structural
link between the ECM and the actin-based cytoskeletal
system of cells [152-156]. Undoubtedly, microarray tech-
nology provides a high throughput platform for the eluci-
dation of drug mechanism in study models.
On a different front, a proteomic study was carried out by
Ma et al. to elucidate the cardiovascular protective role of
Rg1 on ECs [133]. The data show that protein expression
of MEKK-3, reticulocalbin, phosphoglycerate, 6-phos-
phogluconolactonase, zinc finger protein, NSAP1 protein,
recombination-activating protein was increased, while
that of eNOS, and mineralocorticoid receptor (MR) was
decreased upon tumor necrosis factor-α (TNF-α) stimula-
tion of HUVEC. However, Rg1 restored the expression of
these proteins to the normal level. Western blotting and
RT-PCR further validated that NO production in such
TNF-α induced condition was correlated to the increase of
eNOS mRNA and protein expression. They suggest that
the increase of NO is related to the protective role of Rg1
on TNF-α stimulated HUVEC.
Ginsenosides and steroids
Steroid hormones and vascular homeostasis
A critical function of the vasculature is to provide a nutri-
tional supply to tissues and organs. In general, proper vas-
cular homeostasis is controlled by capillary permeability
modulation, vasodilation and angiogenesis [157-159]. All
these activities can govern the rate of material exchange,
transportation and the site of distribution so as to meet
the physiological needs of the human body. Steroid hor-
mones, such as glucocorticoids, estrogens, progestagens,
mineralocorticoids and androgens, play an important role
in such vascular modulation at the molecular, cellular and
even systematic levels [160-164].
Among the various steroid hormones, estrogen is the most
promising example used to elaborate the maintaining and
protective roles of steroid hormones on vascular homeos-
tasis and cardiovascular disorders. The growing evidence
implicated that estrogen reduces the risk of atherosclerosis
by (1) decreasing the serum levels of both total and low-
density-lipoprotein (LDL) cholesterol, while raising those
of high-density-lipoprotein (HDL) cholesterol and triglyc-
erides; (2) interfering with the inflammatory processes
(e.g. monocyte adherence and trans-endothelial migra-
tion on the endothelium) in the vasculature; and (3) act-
ing as an antioxidant [165-168]. Furthermore, estrogen is
also a potent vasodilator, and hypotensive agents that can
induce vascular relaxation by producing an increase of
endothelium-derived vasodilators (e.g. NO). Mechanistic
studies clearly indicate that while estrogen binds with its
corresponding steroid hormone receptor – estrogen recep-
tor (ERα, and ERβ), it may undergo either or both
genomic and non-genomic actions inside the cells.
Through the conventional pathway, activated-ER induces
the gene transcription of eNOS, thereby increasing NO
generation. Alternatively, through triggering the intracel-
lular signaling (non-genomic) pathway, phosphorylated
estrogen-bound ER (ligand-activated ER) has been found
to induce rapid endothelial NO release via the PI3K-Akt-
dependent pathway in HUVEC [169,170]. Various ginse-
nosides have been shown to exhibit an estrogen-like activ-
ity by acting as a functional ligand of ER [171-174].Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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Ginsenosides-mediated steroid-like activities
Ginsenosides could exhibit their actions through plasma
membrane, cytosol, or even in the nucleus. They can initi-
ate their mode of actions by binding to the membrane
receptors (e.g. ATPase pump, ion transporters and chan-
nels, voltage gated channels and G-proteins) and subse-
quently activating the associated downstream signaling
cascades. As described in the previous section, ginseno-
sides are amphipathic in nature, they can intercalate into
the plasma membrane resulting in the alteration of mem-
brane fluidity and trigger a series of cellular responses.
Binding with the intracellular steroid hormone receptors
including glucocorticoid receptor (GR), estrogen receptor
(ER), progesterone receptor (PR), androgen receptor (AR)
and mineralocorticoid receptor (MR), using their hydro-
phobic 'steroid-like' backbone is another alternative to
trigger cellular responses. Like other steroids, ginsenosides
can gain access to the nuclear receptors, where they regu-
late gene transcription by binding with the specific gene
response elements to activate the so called 'genomic path-
way' [175,176] (Figure 6).
A previous study indeed demonstrated that Rg1 can trans-
activate glucocorticoid response element (GRE)-luciferase
activity by acting as a functional ligand of the GR [177].
Glucocorticoids (GCs) have been reported to activate the
phosphatidylinositol-3 kinase (PI3K)/Akt pathway after
binding with the GR [178]. Interestingly, our recent find-
ings also indicate that Rg1 can act as GCs to increase the
phosphorylation of GR, PI3K, Akt/PKB and eNOS, leading
to an enhancement of NO production in HUVEC (Figure
7). Activation of eNOS was abolished by differential inhi-
bition using RU486 (GR antagonist), LY294002 (PI3K
inhibitor) and SH-6 (Akt inhibitor), indicating that Rg1
induced NO production from eNOS via the PI3K/Akt
pathway. Moreover, knockout of GR by siRNA completely
eliminated such reaction. Taken together, we concluded
that such NO generation pathway was mediated through
the activation of GR by ginsenoside Rg1  [179]. This
nuclear receptor mediated response, which occurs within
seconds or minutes upon stimulation and is independent
of any transcriptional activity, is classified as the 'non-
genomic' pathway [175,176] (Figure 6).
In a later study, we discovered that the angiogenic Rg1 was
able to enhance VEGF expression in ECs by increasing the
level of β-catenin within the nucleus. We concluded that
Rg1 induced increase of VEGF in HUVEC through activa-
tion of a PI3K/Akt → GSK3β→β-catenin/TCF pathway via
GR [180]. In addition, the PI3K/Akt-mediated NO gener-
ation has been found in androgen-responsive LNCaP and
estrogen-responsive MCF-7 cells by others [181]. Re was
found to bind with steroid hormone receptors (including
AR, ERα and PR). Lee et al., however, showed that ginse-
noside Rh1 could only activate ER in the CV-1 cell model
[173].
The estrogen-like activity of various ginsenosides includ-
ing Rg1, Rh1 and Rb1 has been reported [170-172]. In fact,
ginseng has been used in TCM for alleviation of the symp-
toms of menopause, which means ginseng, probably gin-
senosides, can act as phytoestrogens to elicit an ER-
mediated pathway for protecting the cardiovascular sys-
tem. These recent research findings clearly indicate that
ginsenosides may act as steroid hormones to activate var-
ious steroid hormone receptors to exert these pleiotropic
responses. Although many mechanisms behind the phys-
iological effects induced by ginsenosides are still not clear,
their ability to interact with steroid hormone receptors
may hold the key to finally elucidate these diverse actions
of ginseng.
Conclusion
At present, ginseng is not only used as a therapeutic by tra-
ditional medical practitioners but is also as health supple-
ments readily available in the commercial market. The
diversity of highly desirable physiological effects of gin-
seng has intrigued scientists for years. In general, most of
its pharmacological actions have been attributed to a
group of triterpenoid saponins called ginsenosides.
Although the modulatory effects of ginseng or probably
ginsenosides have been extensively investigated, the
actual molecular mechanisms remain largely unknown.
Recently, it has been found that ginsenosides can act as
functional ligands to activate different steroid hormone
receptors. Through such mechanisms, ginseng can exert its
effects on the human body by acting in a similar way as
the steroid hormones. The interaction between ginseno-
sides and various nuclear steroid hormone receptors may
explain the diverse activities of ginseng, which may even-
tually lead to further development of ginseng-derived
therapeutics for angiogenesis-related diseases.
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Schematic overview of ginsenosides-mediated genomic and non-genomic pathways Figure 6
Schematic overview of ginsenosides-mediated genomic and non-genomic pathways. Ginsenosides possess a ster-
oid-like skeleton composed of four trans-rings with different degrees of glyco-substitution. They are amphipathic in nature and 
can exhibit their actions at different cellular locations; such as the plasma membrane, cytosol and nucleus. Through the non-
genomic pathway (indicated by red arrows), (i) they can initiate their actions by binding with the transmembrane receptors 
(e.g. ATPase pump, ion transporters and channels, voltage-gated channels and G-proteins) and subsequently activating the 
associated downstream signaling cascades. Moreover, they can intercalate into the plasma membrane resulting in an alteration 
of membrane fluidity and a trigger of a series of cellular responses. (ii) binding with steroid hormone receptors (SHRs) includ-
ing glucocorticoid receptor (GR), estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and mineralo-
corticoid receptor (MR) present inside or outside the nucleus by using their hydrophobic backbone is another alternative to 
trigger downstream cellular responses. Those activated (phosphorylated) SHRs can activate the target molecules through a sig-
naling cascade that brings about various cellular responses. (iii) the ligand-bound SHRs can translocate into the nucleus, where 
they regulate gene transcription by binding with the specific Response Elements (XRE). This is the so called 'genomic pathway' 
(indicated by blue arrows). Consequently, the altered gene products can affect the final cellular responses.Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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Schematic overview of ginsenoside Rg1-mediated angiogenic action in HUVEC Figure 7
Schematic overview of ginsenoside Rg1-mediated angiogenic action in HUVEC. Ginsenoside Rg1, which acts as a 
functional ligand of glucocorticoid receptor (GR) (either cytosol GR or membrane-bound GR-mGR), promotes angiogenesis 
through both non-genomic and genomic pathways. Through the non-genomic pathway, it increases nitric oxide (NO) produc-
tion via the PI3K-Akt pathway: GR → phosphatidylinositol-3 kinase (PI3K)/Akt pathway → endothelial nitric oxide synthase 
(eNOS) pathway. Rg1 also increases vascular endothelial growth factor (VEGF) production through the GR → PI3K/Akt → 
GSK3β → β-catenin/TCF pathway. Gene expression profiling data indicated that Rg1 could increase the expression of a group 
of genes (e.g. Rho A, RhoB, IQGAP1, LAMA4, CALM2 and Vav2) which are related to cell-cell adhesion, migration and 
cytoskeletal remodeling.Chinese Medicine 2007, 2:6 http://www.cmjournal.org/content/2/1/6
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